Last reviewed · How we verify
NCT03030729
Macular Thickness Measurements Using Retinal-thickness OCT
trial in Age-Related Macular Degeneration in 14 participants. Completed in 14 January 2018.
14 January 2018
Quick facts
| Lead sponsor | Notal Vision Ltd. |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 14 |
| Start date | 14 March 2017 |
| Primary completion | 14 January 2018 |
| Estimated completion | 14 January 2018 |
| Sites | 1 location across Israel |
Conditions studied
- Age-Related Macular Degeneration — all drugs for Age-Related Macular Degeneration →
- Diabetic Retinopathy — all drugs for Diabetic Retinopathy →
Sponsor
Notal Vision Ltd.
Who can join
18 and older, any sex, with Age-Related Macular Degeneration or Diabetic Retinopathy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Comparison between retinal measurements, done by the RT (Retinal Thickness) imaging and a commercial OCT (Optical Coherence Tomography)
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03030729
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Age-Related Macular Degeneration
Currently open trials in the same condition.
- NCT07440225 — A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002) · Phase 2, PHASE3 · recruiting
- NCT06619405 — AMD and Validation Rod-Meditated Dark Adaptation With Everyday Task Performance · NA · recruiting
- NCT06970665 — A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Ma · Phase 4 · recruiting
- NCT06319872 — The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration · Phase 1 · recruiting
- NCT06662162 — Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration · NA · recruiting
Other Notal Vision Ltd. trials
Trials by the same sponsor.
- NCT04241198 — Home Retinal Imaging Using NOTAL-OCT V3.0 · completed
- NCT04078672 — Retinal Imaging Using NOTAL-OCT V3.0 · NA · completed
- NCT03969303 — NOTAL-OCT V.2.5 vs Commercial OCT in AMD Patients · completed
- NCT03600519 — Retinal Imaging Using NOTAL-OCT V2.5 · completed
- NCT03270865 — Usability and Ergonomic Evaluation of Self-Positioning System for Retinal Imaging · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03030729 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Notal Vision Ltd.
- Last refreshed: 17 June 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03030729.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing